

September 10, 2019

To,  
**Dy. General Manager**  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

To,  
**The Manager – Listing,**  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051.

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sir,

**Sub: Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation)**

With reference to the subject mentioned above, kindly find attached media release which is self explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

**Encl: as above**

**Press Release**

**For Immediate Release**

## **Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation)**

**Mumbai, India; September 10, 2019:** Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux<sup>®1</sup>-E Foam, 0.05%, of Mylan Pharmaceuticals Inc.

According to IQVIA<sup>™</sup> sales data for the 12 month period ending July 2019, the Olux<sup>®</sup>-E Foam, 0.05% market<sup>2</sup> achieved annual sales of approximately \$11.1 million\*.

Glenmark's current portfolio consists of 161 products authorized for distribution in the U.S. marketplace and 54 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

<sup>1</sup>All brand names and trademarks are the property of their respective owners.

<sup>2</sup>Market includes brand and all available therapeutic equivalents

\*IQVIA<sup>™</sup> National Sales Perspectives: Retail & Non-Retail, July 2019

--End--

### **About Glenmark Pharmaceuticals**

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

### **For further information, please contact:**

Harsh Sheth

Glenmark, Mumbai, India

Tel: +91 22 4018 9999

Email: [corpcomm@glenmarkpharma.com](mailto:corpcomm@glenmarkpharma.com)